Ergotamine inhalation - Sheffield
Alternative Names: Tempo-ergotamineLatest Information Update: 24 Oct 2021
At a glance
- Originator Sheffield Pharmaceuticals
- Class Antimigraines; Ergot alkaloids; Vasoconstrictors
- Mechanism of Action Alpha adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 17 Jun 2003 Sheffield Pharmaceuticals has filed for protection under Chapter 7 bankruptcy laws
- 17 Jun 2003 Discontinued - Clinical-Phase-Unknown for Migraine in USA (Inhalation)
- 16 Oct 2000 A clinical study has been added to the Advances in the Treatment of Nausea and Migraine pharmacodynamics section